MSC Receives the Second Prize in Biomedical Industry Group of Fifth China Innovation & Entrepreneurship Competition

Xiamen, China - MicroPort Sorin CRM (Shanghai) Co., Ltd. ("MSC"), a joint venture of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") and Italy-based Sorin Group, received the second prize in the Biomedical Industry Group of Fifth China Innovation & Entrepreneurship Competition, after the furious final held from November 24 to November 28 in Xiamen of Fujian Province. It is another award MSC was granted in such national contest, following the "Best Investment Value Award" and the "Winning Prize in Enterprise Group" it received in the Shanghai Division Contest in September.
 
Officially launched in July, the Fifth China Innovation & Entrepreneurship Competition had 34,341 participants including 22,277 companies and 12,064 teams, and among them 3,924 enterprises and 1,039 teams were from the biomedical industry. A total of 179 enterprises and 35 teams went through to the final after over months of fierce competition in the preliminaries, semifinals and finals of contests of various divisions. In the Shanghai Division Contest, MSC received the "Best Investment Value Award" and the "Winning Prize in Enterprise Group," and successfully advanced to the final of the Fifth China Innovation & Entrepreneurship National Competition.
 
Participating enterprises and teams presented their projects to the judges, experts, investors, and entrepreneurs, which were fully assessed by their technology values, market potentials, and investment values. After one day of heated contest, MSCs "Self-Developed and Domestically Made BonaFire® Pacing Lead System" managed to stand out and won the second prize in the Biomedical Industry Group of Fifth China Innovation & Entrepreneurship Competition with its self-developed technology, the huge potential of the pacemaker market and high expectations of the substitution of imported pacemakers by domestically innovated ones. Such award shows the judges' full recognition on MSC's teamwork and is also a strong encouragement to the company.
 
BonaFire® has independent intellectual property right, and its design conforms to international standards with excellent structure design, material selection and manufacturing technique. It is so far the thinnest pacing lead in China, largely reduces the damage to blood vessels. The device can be mass produced with the support of MSC's pacemaker production line that is the first world-class cardiac pacemaker production line in China. Currently, 15 cases of BonaFire®'s feasibility study have been completed, and its large-scale clinical trial will be carried out soon. Once proved in clinical trials and granted regulatory approval, BonaFire® will provide Chinese patients with pacing leads of world-class quality and affordable price.